Takamatsu Kiyoshi, Ogawa Mariko, Higuchi Tsuyoshi, Takeda Takashi, Hayashi Kunihiko, Mizunuma Hideki
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Sugano 5-11-13, Ichikawa-City, Chiba 272-8513, Japan.
Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Zaifu-cho 5, Hirosaki-City, Aomori 036-8562, Japan.
Evid Based Complement Alternat Med. 2020 Jul 11;2020:9285317. doi: 10.1155/2020/9285317. eCollection 2020.
Kampo medicine, a traditional Japanese medicine, is widely used in Japan, especially in the field of menopause medicine. However, few studies have shown evidence-based effects. This study aimed to confirm the effects of kamishoyosan on menopausal symptoms with a randomized, placebo-controlled, double-blind clinical trial.
Subjects were randomly allocated to groups that received either kamishoyosan ( = 101) or a placebo resembling kamishoyosan ( = 104). The primary outcomes were the change in the number of hot flashes, depression scores, improvements of anxiety, quality of life (QOL), and menopausal symptoms before and 4 and 8 weeks after initiation of treatment with the study drug. The secondary outcome was drug safety.
After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups. The changes in SDS scores showed the same results. Moreover, no significant differences were observed between the two groups in assessments with the STAI, SF-36, and JSOG menopausal index. No serious adverse effect was reported.
This first placebo-controlled double-blind randomized trial with kamishoyosan demonstrated that it was safe and had some effects on climacteric symptoms, but not significant compared with placebo. Some problems, such as placebo effects, in the study of Kampo therapy for menopausal symptoms, were revealed. This trial is registered with the trial registration number. UMIN 000006042.
汉方医学作为一种传统的日本医学,在日本被广泛应用,尤其是在更年期医学领域。然而,很少有研究能证明其有循证效果。本研究旨在通过一项随机、安慰剂对照、双盲临床试验来证实加味逍遥散对更年期症状的疗效。
将受试者随机分为两组,一组服用加味逍遥散(n = 101),另一组服用外观类似加味逍遥散的安慰剂(n = 104)。主要观察指标为潮热次数的变化、抑郁评分、焦虑改善情况、生活质量(QOL)以及在开始服用研究药物前、用药4周和8周后的更年期症状。次要观察指标为药物安全性。
8周后,两组治疗后潮热次数均减少,但两组间无显著差异。抑郁自评量表(SDS)评分的变化也显示了相同的结果。此外,在使用状态特质焦虑问卷(STAI)、健康调查简表(SF - 36)和日本更年期学会指数(JSOG)进行评估时,两组间未观察到显著差异。未报告严重不良反应。
这项首次以加味逍遥散为研究对象的安慰剂对照双盲随机试验表明,加味逍遥散是安全的,对更年期症状有一定作用,但与安慰剂相比无显著差异。同时揭示了在汉方疗法治疗更年期症状研究中存在的一些问题,如安慰剂效应等。本试验已在试验注册机构注册,注册号为UMIN 000006042。